

Concept for Establishing a Diabetes Complete Remission and Me-Byo (Pre-Disease) Treatment Center in Dubai

- Delivering Research Outcomes to Patients Worldwide and to a Healthy Longevity Society -

Biozipcode Inc.

2026.6.1

Business Concept

In Dubai, UAE, this project will develop, in phases, a treatment center that integrates medical care pursuing the possibility of complete diabetes remission with Me-Byo, prevention, and wellness. Initially, it will use partner clinics and hotels to provide glucose-metabolism assessment, lifestyle improvement, CGM, nutrition, exercise, sleep support, and online follow-up under physician supervision. Research-stage 5-ALA studies, diabetic stem cell biomarkers, and Biozipcode™ technology will be clearly distinguished from general medical care and carefully positioned as future diagnostic-support and R&D elements.

1. Market Opportunity and Why Dubai

Approx. 589M Global Diabetes Patients IDF estimate. Projected to increase to approx. 853 million by 2050.	Approx. 1.3M Diabetes Pat. in the UAE IDF estimate. Projected to increase to approx. 1.9 million by 2050.	Approx. 690K Dubai Medical Tourists Announced by DHA in 2023. Medical spending exceeded AED 1 billion .
---	---	---

Diabetes is a global social issue affecting healthcare costs, complications, labor productivity, and healthy life expectancy. Before onset, the Me-Byo stage often involves accumulated changes such as glucose fluctuations, obesity, visceral fat, sleep deprivation, chronic fatigue, and physical inactivity. This concept builds a new support model in Dubai that integrates medical care and wellness from the Me-Byo stage, going beyond conventional diabetes

management.

Dubai brings together DHA, Dubai Healthcare City, international patients, high-net-worth individuals, hotels and resorts, family offices, and investor networks, making it well suited to combine medical tourism with high-value healthcare. In the initial phase, verification can proceed while limiting large fixed investment by partnering with existing clinics and hotels.

2. Target Customers and Value Proposition

Main Target Customers	Value Proposition
<ul style="list-style-type: none"> - Type 2 diabetes patients and people with prediabetes - People with obesity, visceral fat, or lifestyle-disease risks - Executives, high-net-worth individuals, overseas patients, and family office stakeholders - Individuals interested in healthy longevity, longevity, and Me-Byo care - Corporate health-management and executive health programs 	<ul style="list-style-type: none"> - Glucose-metabolism and complication-risk assessment under physician supervision - Visualization of daily glucose fluctuations using CGM and related tools - Ongoing support covering nutrition, exercise, sleep, and stress - Dubai-based residential medical retreats - Connecting research outcomes to future diagnostic support and biomarkers

3. Programs Offered

<p>Medical Program Pursuing Complete Diabetes Remission</p>	<p>Integrates blood glucose, HbA1c, C-peptide, insulin secretion, complication risk, CGM, and nutrition, exercise, and sleep guidance. It does not guarantee complete remission; it respects existing treatment and proceeds under physician supervision.</p>
<p>Me-Byo and Prediabetes Program</p>	<p>Assesses glucose fluctuations, weight, visceral fat, diet, sleep, exercise, and chronic-inflammation risk before diabetes onset, and</p>

	supports preventive lifestyle improvement.
Medical Retreat	Designed as a residential program of several days to several weeks in partnership with Dubai hotels and resorts. Combines testing, medical consultation, diet, exercise, sleep improvement, and post-return follow-up.
Executive Longevity	For executives and high-net-worth individuals, this program comprehensively evaluates glucose metabolism, fatigue, sleep, body composition, nutrition, physical function, and stress, and provides improvement plans suited to real daily life.
Research Collaboration Program	5-ALA research, diabetic stem cell biomarkers, and Biozipcode™ technology are positioned as research-stage elements and connected to future diagnostic support, subject to ethics review and regulatory confirmation.

4. Revenue Model and Partnership Strategy

Short-Term Revenue	Medium-Term Revenue	Long-Term Revenue
Initial testing and health assessment; 1- to 3-month diabetes and Me-Byo programs; CGM; nutrition, exercise, and sleep guidance; online follow-up.	Medical retreats, executive longevity, corporate health-management programs, and membership-based follow-up.	Program provision to partner clinics, hotel joint packages, biomarker joint research, and future licensing models.

5-ALA-related products and supplements will be handled carefully within the lawful scope, without making pharmaceutical-like efficacy claims, after confirming UAE requirements for import, labeling, advertising, and use within medical institutions.

5. Launch Steps

Time	Focus Theme	Main Actions	Outcome Goals
Year 1	Regulatory Confirmation and Pilot	Confirm DHA and other regulations, develop partner clinics, hotels, and testing companies, and launch a small-scale program.	Verify service scope, pricing, safety, and operating structure.
Year 2	Retreat and Center Preparation	Launch small-group retreats with hotel partners, corporate health management, and define candidate site, staffing, and equipment for a dedicated center.	Create joint packages and finalize the dedicated-center plan.
Year 3	Dedicated Center and Internationalization	Open the dedicated Dubai center, launch membership-based online follow-up, build UAE-Palau-Japan collaboration, and standardize programs.	Establish a base for international patient intake, corporate contracts, and future licensing.

6. Potential Partners

Potential partners include clinics and hospitals in Dubai, Dubai Healthcare City-related facilities, wellness hotels and luxury resorts, medical tourism operators, testing companies, nutrition, exercise and rehabilitation specialists, universities and research institutions, investors and family offices, and government or public institutions. Partner selection will prioritize medical safety, regulatory readiness, international patient handling, data management, research ethics, and service quality for high-net-worth clients over name recognition alone.

7. Investment Plan and Use of Funds

Model	Description	Estimated 3-Year Budget
Minimum	Centered on partner clinics. Start with a small pilot and limited retreats.	JPY 300-500 million
Standard	Build results through partner clinics, then open a dedicated center from Year 2 onward.	JPY 700 million-1.2 billion
Full Rollout	Proceed in parallel with the dedicated center, hotel partnerships, research data infrastructure, and preparation for international expansion.	JPY 1.2-2.0 billion

Initial funding should be based on the standard model. A realistic staged investment approach would first use a first tranche for regulatory confirmation, partner development, pilot operations, and detailed investor DD, then move to dedicated-center funding after confirming actual results.

Regulatory / Legal	Medical Operations	IT / Data	Business Development
Medical licenses, advertising, pharmaceutical regulations, data protection, contract DD	Physicians, nurses, nutrition, exercise, rehab specialists, testing costs	Patient management, online follow-up, CGM, research data management	Partner development, hotel joint products, overseas patient support, PR

8. Appeal for Investors

<p style="text-align: center;">Cross-Sector Growth Area</p> <p>Integrates diabetes, Me-Byo, longevity, and medical tourism, expanding the target beyond patients to prediabetes populations, high-net-worth individuals, and corporations.</p>	<p style="text-align: center;">Composite Revenue Model</p> <p>Combines testing, treatment, retreats, memberships, corporate contracts, partner provision, and future licensing in phases.</p>
<p style="text-align: center;">Connection to R&D</p> <p>Connects 5-ALA, biomarkers, and Biozipcode™ technology as future diagnostic-support and R&D elements, not as established medical care.</p>	<p style="text-align: center;">Foundation for International Expansion</p> <p>Allows role sharing among the UAE as a business and medical-tourism hub, Palau as a regional demonstration site, and Japan as a research, IP, and quality-control base.</p>

9. Compliance Policy

This project does not guarantee complete diabetes remission. Services will be provided under physician supervision, and patients will not be encouraged to stop medication, insulin, or clinic visits based on self-judgment. No efficacy claims will be made for 5-ALA or supplements, and pharmaceutical, food, and advertising regulations in the UAE, Japan, Palau, and other relevant jurisdictions will be confirmed. Diabetic stem cell biomarkers and Biozipcode™ technology will be treated as research-stage elements and clearly distinguished from general medical care.

10. Next Actions

<p style="text-align: center;">1. Local DD</p> <p>Confirm DHA/DHCC requirements, medical advertising, pharmaceutical regulations, data protection, and partner clinic conditions.</p>	<p style="text-align: center;">2. Pilot Design</p> <p>Define target patients, pricing, test items, CGM, physician structure, and retreat flow.</p>	<p style="text-align: center;">3. Investment Terms Discussion</p> <p>Discuss staged investment, joint venture, strategic investment, and MOU based on the standard model.</p>
--	---	--